Michael Rieder

Children's Health & Therapeutics Dr. Michael Rieder
Scientist
Photo

Affiliations

Scientist, Division of Children’s Health and Therapeutics, Children’s Health Research Institute               Chair, Department of Paediatrics, Schulich School of Medicine & Dentistry, Western University                                                                                                                                                    CIHR-GSK Chair in Paediatric Clinical Pharmacology
Professor, Departments of Paediatrics, Physiology & Pharmacology and Medicine, Schulich School of Medicine & Dentistry, Western University
Associate Scientist, Robarts Research Institute, Western University
Research Associate, Cameron Institute  Cheif, Department of Paediatrics, Schulich School of Medicine & Dentistry, Western University

How my research helps children

Our research is on Personalized Medicine for children with the focused goal of drug safety. Drug treatment has made a huge difference in the lives of children, but serious side effects are common problems in the treatment of many common and important diseases in children. The reasons that these side effects develop and how to predict which children are at risk are largely unknown. We are studying how serious drug side effects occur with the goal of developing strategies to better diagnose, treat and predict these serious side effects in order to make drug therapy for children both safer and more effective.

Research

Current Research Activities

We have a number of research projects underway in the area of Personalized Medicine for Children. Our research is done in collaboration with a number of investigators, bringing synergistic skills to address fundamental questions.

Our laboratory has a long-standing interest in understanding the mechanisms of drug hypersensitivity, and is currently the only laboratory in North America studying the mechanisms of lymphocyte toxicity to reactive drug metabolites in primary patient cells. We have recently developed a novel assay for drug hypersensitivity using platelets as the target tissue.

Other projects currently being undertaken by our laboratory in collaboration with fellow investigators include studying the impact of anticonvulsant therapy on vascular health, identifying novel biomarkers for disease and drug exposure, studying how viral infection, with special reference to HIV infection, alters the ability of cells to deal with drugs and drug metabolites, understanding the mechanisms of drug-induced renal injury and how to reduce the risk of drug-induced kidney damage, studying the use of saliva for monitoring drug therapy and a series of studies on the genetic determinants of serious drug reactions, notably among children receiving chemotherapy for cancer. We are also studying the metabolism and kinetics of steroids in a number of conditions, including asthma and rheumatic diseases in childhood.

Research Team

Our research team includes our core staff and a number of trainees. Anda Marcu is our technician and Becky Malkin is our research pharmacist. Blance del Pozza, a paediatric dermatologist who trained in Mexico, is our post-doctoral fellow. We have a number of graduate students including Abdelbaset A Elzagallaai, Kemi Adeyanju and Lauren Hanley in the Doctoral program and Nada Tabarra, Rachel Gow, Laura Cheng and Katherine Cizkowski in the Masters program. We also have a number of undergraduate and summer students.

We have trained a large number of graduate students and post-doctoral fellows, including Dr. David Hess (Assistant Professor, Western University), Dr. Michelle Aarts (Assistant Professor, York University), Dr. Nancy Chen (Research Scientist, Merck), Dr. Simerpal Gill (Centers for Disease Control) and Dr. Adriana Krizova (Department of Pathology, University of Toronto).

Future Research Plans

Our research plans include studies of the role of drug transporters in serious adverse reactions to chemotherapy among children with cancer and strategies to identify children at risk. We also plan to study the immune determinants of drug hypersensitivity with special reference to serious drug-induced skin rash. Our plans also include extending the range of drugs we are evaluating for drug-induced renal injury to include antiviral drugs.

Over the longer time, we plan to study how best to implement Personalized Medicine approaches to the therapy of common and important diseases in children, and how this approach can increase efficacy, reduce side effects and enhance quality of life.

Awards & Grants

Awards & Grants

Funding in support of Surveillance Core – Awarded by Canadian Institutes of Health Research (CIHR)/DSEN

Funding in support of Pharmacogenomics Core – Awarded by Canadian Institutes of Health Research (CIHR)/DSEN

Funding in support of Point of Care Testing – Awarded by Adept Diagnostics

Funding in support of Development of and Barriers to Gene-Based Drug Reactions – Awarded by Canadian Institutes for Health Research (CIHR) Knowledge Translation Grant

Funding in support of Genetics of Serious Cutaneous Adverse Drug Reactions – Awarded by Canadian Dermatology Foundation

Funding in support of Kinetics of steroids in asthma and children – Awarded by PSI Foundation

Funding in support of Vincristine neurotoxicity – Awarded by Canadian Institutes for Health Research (CIHR) Catalyst Grant

Faculty Scholar Award – Awarded by Schulich School of Medicine & Dentistry, The University of Western Ontario

Funding in support of GSK-Endowed Chair in Paediatric Clinical Pharmacology – Awarded by Canadian Institutes of Health Research (CIHR)

Funding in support of Canadian Pharmacogenomics Network for Drug Safety (CPNDS) – Awarded by CIHR

Funding in support of Use of Complementary Therapy with Traditional Chinese Medicine to Reduce Adverse Drug Reactions – Awarded by Ministry of Science Technology and Innovation

Funding in support of Concurrent Therapy with Antioxidants Derived from Traditional Chinese Medicine to Reduce Risk of Serious Adverse Drug Reactions – Awarded by Physician Services Incorporated Foundation (PSI)

Funding in support of Comparison of Ketamine versus Ketamine-Propofol for Procedural Sedation in Children – Awarded by PSI

Funding in support of Reducing Vaccination Pain – Awarded by CIHR

Funding in support of Help Eliminate Pain in Kids: Conquering Childhood Immunization Pain – Awarded by CIHR

Funding in support of Reducing risk of adverse drug reactions in children by use of Traditional Chinese Medicine – Awarded by CIHR

Funding in support of Genetic approaches to adverse drug reactions in children – Awarded by Genome Canada

Recent Publications

Publications

Palatability, adherence and prescribing patterns of antiretroviral drugs for children with human immuno deficiency virus infection in Canada
Lin D, Seabrook JA, Matsui DM, King SM, Rieder MJ, Finkelstein Y
Pharmacoepidemiol Drug Saf. 2011 Dec;20(12):1246-52

Canadian Pharmacogenomics Network for Drug Safety Consortium. Genetic determinants of anthracycline cardiotoxicity in children
visscher H, Ross CJ, Rassekh SR, Barhdadi A, Dube MP, Al-Saloos H, Sandors GS, Caron HN, van Dalen EC, Kremer LC, van der Pal HJ, Brown AM, Rogers PC, Phillips MS, Rieder MJ, Carleton BC, Hayden MR
J Clin Oncol. 2011 Oct 11

Hair cortisol as a biological market of chronic stress: current status, future directions and unanswered questions
Russell E, Koren G, Rieder M, Van Uum S
Psychoneuroendocrinology. 2011 Oct 3

In vitro testing for hypersensitivity-mediated adverse drug reactions: challenges and future directions
Rieder MJ
Clin Pharmacol Ther. 2011 Sep; 90(3):455-60

The effect of N-acetylcysteine on the anti-tumour activity of ifosfamide
Chen N, Hanly L, Rieder MJ, Yeger H, Koren G
Can J Physiol Pharmacol. 2011; 89:335-43

Pharmacokinetics of prednisolone in childhood-onset systemic lupus erythematosus (cSLE)
Sherwin CMT, Sagcal-Gironella ACP, Tirona RG, Rieder MJ, Brunner HI, Vinks AA
Clin Ther. 2011; 33(10):1524-36

Cutaneous adverse drug reactions in children: An analysis of reports from the Canadian Pharmacogenomics Network for Drug Safety
Castro-Pastrana L, Ghannadan R, Rieder MJ, Dahlke E, Hayden M, Carleton B
J Pop Ther Clin Pharm. 2011; 18:e106-20

A Systematic Review of Treatment of Drug-Induced Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Children
Del Pozzo-Magana B, Lazo-Langner A, Carleton B, Castro-Pastrana L, Rieder MJ
J Pop Ther Clin Pharm. 2011; 18:e121-33

Hair cortisol content in patients with adrenal insufficiency on hydrocortisone replacement therapy
Gow R, Koren G, Rieder MJ, Van Uum S
Clin Endocrinol (Oxf). 2011; 74(6):687-693

Apparent elevated creatinine after ingestion of nitromethane: interference with the Jaffe reaction
Killom E, Lim RK, Rieder MJ
Ther Drug Monit. 2011 Feb; 33(1):1-2

N-acetylcysteine as a Novel Prophylactic Treatment for Ifosfamide-Induced Nephrotoxicity in Children: Translational Pharmacokinetics
Hanly LN, Chen N, Aleksa K, Cutler M, Bajcetic M, Palassery R, Regueira O, Turner C, Baw B, Malkin B, Freeman D, Rieder MJ, Vasylyeva TL, Koren G
J Clin Pharmacol. 2011 Jan 24

A Survey of Canadian Medical Student Attitudes Towards the Ethics of Pediatric Clinical Trials: Are they Different from Canadian and British Health Care Professionals?
Wang D, Bahm AL, Seabrook JA, Sammons HM, Rieder MJ
J Popul Ther Clin Pharmacol. 2011;18(1):e10-6. Epub 2011 Jan 28

Severe bullous hypersensitivity reactions after exposure to carbamazepine in a Han Chinese child with a positive HLA-B*1502 and a negative lymphocyte toxicity assay: Evidence for different pathophysiological mechanisms
Elzagallaai B, Garcia-Bournissen F, Finkelstein Y, Bend JR, Rieder MJ, Koren G
J Pop Therap and Clin Pharm. 2011; 18(1):e1-9. Epub 2011 Jan 28

The In Vitro Platelet Toxicity Assay (iPTA): A Novel Approach for Assessment of Drug Hypersensitivity Syndrome
Elzagallaai AA, Rieder MJ, Koren G
J Clin Pharmacol. 2010 Apr 16. [Epub ahead of print]

Adderall and cardiovascular risk: A therapeutic dilemma
Sichilima T, Rieder MJ
Paediatr Child Health. 2009 Mar;14(3):193-5

Relationship between antiepileptic drugs and biological markers affecting long-term cardiovascular function in children and adolescents
Cheng LS, Prasad AN, Rieder MJ
Can J Clin Pharmacol. 2010 Winter;17(1):e5-46

Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy
Ross CJ, Katzov-Eckert H, Dubé MP, Brooks B, Rassekh SR, Barhdadi A, Feroz-Zada Y, Visscher H, Brown AM, Rieder MJ, Rogers PC, Phillips MS, Carleton BC, Hayden MR
CPNDS Consortium Nat Genet. 2009 Dec;41(12):1345-9

Inadequate pain management during routine childhood immunizations: the nerve of it
Taddio A, Chambers CT, Halperin SA, Ipp M, Lockett D, Rieder MJ, Shah V
Clin Ther. 2009;31 Suppl 2:S152-67

Effectiveness and tolerability of pharmacologic and combined interventions for reducing injection pain during routine childhood immunizations: systematic review and meta-analyses
Shah V, Taddio A, Rieder MJ
HELPinKIDS Team Clin Ther. 2009;31 Suppl 2:S104-51

In vitro testing for the diagnosis of anticonvulsant hypersensitivity syndrome: a systematic review
Elzagallaai AA, Knowles SR, Rieder MJ, Bend JR, Shear NH, Koren G
Mol Diagn Ther. 2009;13(5):313-30

Life-threatening flecainide intoxication in a young child secondary to medication error
D'Alessandro LC, Rieder MJ, Gloor J, Freeman D, Buffo-Sequiera I
Ann Pharmacother. 2009 Sep;43(9):1522-7

Immune mediation of hypersensitivity adverse drug reactions: implications for therapy
Rieder MJ
Expert Opin Drug Saf. 2009 May;8(3):331-43

Patch testing for the diagnosis of anticonvulsant hypersensitivity syndrome: a systematic review
Elzagallaai AA, Knowles SR, Rieder MJ, Bend JR, Shear NH, Koren G
Drug Saf. 2009;32(5):391-408

Additional publications

Contact

Contact

Phone: (519) 685-8500, x58293
Fax: (519) 685-8156
Email: mrieder [at] uwo [dot] ca
Website: http://www.robarts.ca/biotherapeutics/Rieder.htm / https://www.schulich.uwo.ca/paediatrics/faculty/michael-rieder

(Please note: CHRI is not responsible for the content of any external sites - links will open in new window)